Rare cannabinoid gives relief for diabetes in studies

464 0

The cannabinoid cannabimovone continues to receive more support for its health properties

There has been a recent discussion regarding the effects that cannabis could have in treating diabetes and some testimonies and few indirect studies are supporting that assertion. A recent research published by the Biomolecular Chemistry in Italy, and published in the journal Molecules, discovered a rare cannabinoid that can sensitize cells to insulin again. The name of the cannabinoid is cannabimovone (CBM), and it is another cannabis compound with the potential to become a source for diabetes prevention.

More than 34 million Americans suffer from this metabolic disease – that’s nearly 10% of the total population. This discovery is beneficial for Type 2 diabetes since patients can’t seem to process sugar in a normal way for both genetics and lifestyle factors. These patients either don’t produce enough insulin or the receptive cells become resistant to insulin.

Cannabis has been long associated with an increased appetite; however, other studies have found that regular consumers tend to have lower BMI and smaller waists than people who don’t use cannabis. There has also been a connection between cannabis use and lower levels of insulin resistance, which seems like a good way to prevent disease development. CBM is not present in most strains of cannabis plantsñ it was first isolated from a variety of Italian hemp back in 2010, and scientists were able to synthesize the molecule in the lab.

This is just the first step in the research for a cannabis-based medication that’s effective in treating diabetes. Another achievement from the study was a preliminary evaluation of its toxicity. This test was done by exposing the cannabinoid to a group of kidney cells, and it was found safe, even at higher levels. The next step will be to compare the effectiveness of the compound with the common medications used to treat diabetes.